nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Clinical Experience With Endothelin Antagonists 1 1 The authors’ research in this area is currently supported by grants from the British Heart Foundation, the High Blood Pressure Foundation, the Scottish Office, and the Wellcome Trust.
|
Webb, David J |
|
1998 |
11 |
4S2 |
p. 71S-79S nvt p. |
artikel |
2 |
Editorial
|
|
|
1998 |
11 |
4S2 |
p. 69S-70S nvt p. |
artikel |
3 |
Endothelin Inhibition as a Biologic Target for Treating Hypertension
|
Brunner, Hans R |
|
1998 |
11 |
4S2 |
p. 103S-109S nvt p. |
artikel |
4 |
Mibefradil, a T-Channel–Selective Calcium Antagonist
|
Oparil, Suzanne |
|
1998 |
11 |
4S2 |
p. 88S-94S nvt p. |
artikel |
5 |
Mibefradil, a T-Type Channel-Selective Calcium Antagonist
|
Massie, Barry M |
|
1998 |
11 |
4S2 |
p. 95S-102S nvt p. |
artikel |
6 |
The Physiological and Pharmacological Significance of Cardiovascular T-Type, Voltage-gated Calcium Channels
|
Triggle, David J |
|
1998 |
11 |
4S2 |
p. 80S-87S nvt p. |
artikel |